Parkinson’s Disease (PD) is the second-most common neurodegenerative disease after Alzheimer’s disease. Currently, around 1.1 million people in the US are affected by PD. Researchers …
Parkinson 101
Clinical trials are the engine of medical innovation. Every approved treatment or therapy on the market today began its life in a lab and went …
The right self-care practices can make patients and caregivers confident about making it through the journey when diagnosed with Parkinson’s disease. Self-care, from finding hobbies …
April is Parkinson’s Awareness Month, a time to raise awareness about Parkinson’s disease (PD), support those living with it, and contribute to vital research for …
Parkinson’s disease is a movement disorder of the nervous system that affects millions worldwide, and as researchers continue to unravel its intricacies, the future looks …
24 Sep: Ryan Reynolds Shares His Father’s Early Parkinson’s Symptoms: Subtle Signs His Family Missed
Ryan Reynolds, the charismatic star of “Deadpool & Wolverine,” recently opened up about his father’s battle with Parkinson’s disease, shedding light on the early symptoms …
What this means for the future of Parkinson’s disease On May 23, 2024, Congress officially passed the National Plan to End Parkinson’s Act (H.R.2365/S.1064). The …
This blog discusses Parkinson’s Disease, highlighting its history, characteristics, and ongoing research. Initiatives like the PD GENEration study offer free genetic testing. Gain Therapeutics is developing GT-02287, a potential disease-modifying drug for GBA1-Parkinson’s, with support from prominent foundations and currently conducting clinical trials.
On Thursday, April 13, 2023, The Michael J. Fox Foundation (MJFF) announced a historic breakthrough1 in the development of Parkinson’s disease detection and diagnosis. The …
What is allostery? Allo comes from the Greek allos which meaning “other.” Allosteric binding describes a ligand that binds a protein at a target site …
When was Alzheimer’s disease discovered? Alzheimer’s disease as we know it was first described by Dr. Alois Alzheimer, a German doctor, in 1906. He was …
Alpha-synuclein is a neuronal protein that regulates trafficking and neurotransmitter release. Aggregation of alpha-synuclein is associated with the formation of lewy bodies, which are protein …
Gaucher Disease and Parkinson’s Disease are two distinctly different diseases in terms of their onset, symptoms, and prognosis. Despite these differences these diseases have one …
Parkinson’s Disease is among the most common degenerative brain disorders, affecting millions of people each year in the United States alone. We know that the …
MJFF 2021 Conference: The Michael J. Fox. Foundation (MJFF) has held a Parkinson’s Therapeutics Conference annually every fall, starting from 2009. Due to the COVID-19 …
Just last month, AlphaFold launched their Protein Structure Database, containing high-quality predicted structures of every protein in the human body.
For years, the neuroscience industry has been plagued by a high failure rate of drugs in the clinical stages.